MEdPACTO

Nov, 2024

MIMERET, a Novel Mitochondrial-Targeted Drug, Improves Hepatic Steatosis by Stimulating Mitochondrial Fatty Acid Beta-Oxidation to Prevent Lipid Accumulation

AASLD 2024

Nov, 2024

Vactosertib, a TGF-β signaling inhibitor, in combination with Durvalumab increased mOS in ≥2L treatment of patients with PD-L1-positive advanced NSCLC

SITC 2024

Aug, 2024

The TGFβ type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed/refractory multiple myeloma: a phase 1b trial

Nature Communications

Jul, 2024

Oral transforming growth factor-beta receptor 1 inhibitor vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti-tumor immunity

Cancer Communications

Nov, 2023

Tm4sf19 deficiency inhibits osteoclast multinucleation and prevents bone loss

Metabolism 151

Apr, 2023

Vactosertib combined treatment with T1-44, a PRMT5 activity inhibitor, improves the survival and inhibits tumor invasion of murine pancreatic cancer model

American Association for Cancer Research 2023(AACR 2023)

Feb, 2023

Combination treatment of T1-44, a PRMT5 inhibitor with Vactosertib, an inhibitor of TGF-β signaling, inhibits invasion and prolongs survival in a mouse model of pancreatic tumors

Cell Death and Disease (2023)

Jan, 2023

Discovery of TRD-93 as a novel DRAK2 inhibitor

BULLETIN OF THE KOREAN CHEMICAL SOCIETY

Dec, 2022

MAST4 controls cell cycle in spermatogonial stem cells

Cell proliferation(IF : 8.755)

Dec, 2022

Therapeutic Implications of TGF-β Pathway in Desmoid Tumor Based on Comprehensive Molecular Profiling and Clinicopathological Properties

Cancers

Oct, 2022

ESRP1-regulated isoform switching of LRRFIP2 determines metastasis of gastric cancer

Nature communication

Sep, 2022

Phase 1b Study of Vactosertib in Combination with FOLFOX in Patients with Metastatic Pancreatic Ductal Adenocarcinoma who have Failed First-Line Gemcitabine/nab-Paclitaxel

AACR Special Conference on Pancreatic Cancer 2022

Jan, 2022

Phase 1b Study of Vactosertib in Combination with nal-IRI plus 5FU/LV in Patients with Metastatic Pancreatic Ductal Adenocarcinoma who Failed First-Line Gemcitabine/nab-Paclitaxel

ASCO GI 2022

Nov, 2021

Tumor Microenvironment based on PD-L1 and CD8 T-cell infiltration correlated with the survival of MSS mCRC patients treated vactosertib in combination with pembrolizumab

SITC 2021

Nov, 2021

Spatial analysis of tumor-infiltrating lymphocytes correlates with the response of metastatic colorectal cancer patients treated with vactosertib in combination with pembrolizumab

SITC 2021

Jun, 2021

Efficacy and Safety of Vactosertib and Pembrolizumab Combination in Patients with Previously Treated Microsatellite Stable Metastatic Colorectal Cancer

ASCO 2021

Jun, 2021

Phase 1b trial of Vactosertib in Combination with Pomalidomide in Relapsed Multiple Myeloma: A Corticosteroid-Free Approach by Targeting TGF-β Signaling Pathway

ASCO 2021

Apr, 2021

BAG2 Promotes Tumorigenesis and Metastasis by Regulating the Cathepsin B Cleavage in Triple Negative Breast Cancer Cells

AACR 2021

Apr, 2021

DRAK1 suppresses inflammation induced cervical cancer progression by targeting TRAF6 protein

AACR 2021

Apr, 2021

Beneficial effect of vactosertib combined with nal IRI5 FULV in pancreatic cancer treatment

AACR 2021

Apr, 2021

Genomic and transcriptomic analyses of desmoid tumor reveals enrichment of transforming growth factor beta responsive signature

AACR 2021

Nov, 2020

Vactosertib and Durvalumab as Second or Later Line Treatment for PD-L1 Positive Non-small Cell Lung Cancer: Interim Result

SITC 2020

Sep, 2020

Safety and Efficacy of Vactosertib, a TGFBR1 Kinase Inhibitor, in Combination with Paclitaxel in Patients with Metastatic Gastric Adenocarcinoma

ESMO Congress 2020

May, 2020

A Phase 1 study of TGF-β inhibitor, Vactosertib, in combination with Imatinib in patients with advanced desmoid tumor (aggressive fibromatosis)

ASCO 2020

Nov, 2019

Safety and Preliminary clinical activity of Vactosertib, a selective TGF-β receptor I kinase inhibitor, in combination with Durvalumab in advanced Non-small cell lung cancer patients with low PD-L1 expression

SITC 2019

Nov, 2019

Safety and preliminary clinical activity of Vactosertib, a selective TGF-β receptor I kinase inhibitor, in combination with Pembrolizumab in patients with metastatic colorectal or gastric cancer

SITC 2019

Nov, 2019

TGF-β as a promising therapeutic target for treating Osteosarcoma

Innovation in AYA cancer

Jun, 2018

TGF-β Responsive signature is associated with anti-tumor effect of Vactosertib, a potent oral TGF-β receptor type1(TGFBRI) inhibitor in patients with advanced solid tumors

ASCO 2018